TSO3 Awaits FDA Verdict After Label Submission

This morning, Quebec City based TSO3 (TSX: TOS) updated the markets on the status of their FDA 510(k) filing for their low temperature hospital sterilizer, Sterizone VP4. In a press release, the company stated that it has submitted revised labeling to FDA for both the sterilizer and accessory devices. In August of this year, the […]

Tekmira rises as production of Ebola treatment begins


Shares of Burnaby-based Tekmira (TSX:TKM, NASDAQ:TKMR) are up today after the company late yesterday announced it has started limited GMP manufacture of a new therapeutic that specifically targets the Ebola-Guinea variant, the viral variant responsible for the Ebola epidemic in West Africa. The company says the product should be available by December. In August, the […]

Valeant Q3 could prove it doesn’t need Allergan, says Paradigm


A strong third quarter from Valeant Pharmaceuticals (TSX:VRX) on October 20th could prove to the street that the company’s legacy business is strong and sustainable, says Paradigm Capital analyst Alan Ridgeway. In a research update to clients this morning, Ridgeway maintained his “Buy” rating and $160.00 target on Valeant, implying a return of 39% at […]

Opsens has huge upside, says Paradigm Capital

Opsens CEO Louis Laflamme.

The risk-to-reward ratio on Opsens (TSXV:OPS) is compelling, says Paradigm Capital analyst Alan Ridgeway. In a research update to clients yesterday, Ridgeway maintained his “Buy” rating and one-year target of $2.75 on Opsens, implying a return of 299% at the time of publication. The analyst’s update follows on the heels of Tuesday’s news in which […]

Shares of Tekmira soar after first U.S. Ebola case confirmed


Shares of Tekmira (TSX:TKM, Nasdaq:TKMR) are soaring in after market trading after news broke of the first diagnosis of Ebola in the United States. A patient at Dallas’s Texas Health Presbyterian Hospital has tested positive for Ebola, and is currently being treated. The Centers for Disease Control and Prevention this afternoon confirmed that the infected […]

Sensing An Opportunity: Opsens Poised To Enter Growing Cardiac Market


Back when I was a drug rep, I spent a few days shadowing a cardiologist and was fortunate to spend some time in the cardiac catheterization lab (cath lab). Those were the heady days of drug eluding stents, where companies like Angiotech were soaring on the wide utilization of stents for coronary artery disease. Things […]

Take a wait-and-see approach to Merus Labs, says Paradigm

merus labs chart

The resignation of CEO Elie Farah is a short-term negative for Merus Labs (TSX:MSL), but the company’s lucrative platform remains, says Paradigm Capital analyst Alan Ridgeway. Shares of Merus fell by more than 22% yesterday after Farah’s sudden resignation as CEO and from the company’s board. The company said Barry Fishman, an industry veteran previously […]